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The pathophysiology of heart failure with preserved ejection fraction (HFpEF) remains
incompletely defined. We aimed to characterize HFpEF compared to heart failure with
reduced ejection fraction (HFrEF) and asymptomatic hypertensive or non-hypertensive
controls.
Materials and methods
Prospective, observational study of 234 subjects (HFpEF n = 140; HFrEF n = 46, controls n
= 48, age 73±8, males 49%) who underwent echocardiography, cardiovascular magnetic
resonance imaging (CMR), plasma biomarker analysis (panel of 22) and 6-minute walk test-
ing (6MWT). The primary end-point was the composite of all-cause mortality and/or HF
hospitalization.
Results
Compared to controls both HF groups had lower exercise capacity, lower left ventricular
(LV) EF, higher LV filling pressures (E/E’, B-type natriuretic peptide [BNP], left atrial [LA] vol-
umes), more right ventricular (RV) systolic dysfunction, more focal and diffuse fibrosis and
higher levels of all plasma markers. LV remodeling (mass/volume) was different between
HFpEF (concentric, 0.68±0.16) and HFrEF (eccentric, 0.47±0.15); p<0.0001. Compared to
controls, HFpEF was characterized by (mild) reductions in LVEF, more myocardial fibrosis,
LA remodeling/dysfunction and RV dysfunction. HFrEF patients had lower LVEF, increased
LV volumes, greater burden of focal and diffuse fibrosis, more RV remodeling, lower LAEF
and higher LA volumes compared to HFpEF. Inflammatory/fibrotic/renal dysfunction plasma
markers were similarly elevated in both HF groups but markers of cardiomyocyte stretch/
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damage (BNP, pro-BNP, N-terminal pro-atrial natriuretic peptide and troponin-I) were higher
in HFrEF compared to HFpEF; p<0.0001. Focal fibrosis was associated with galectin3,
GDF-15, MMP-3, MMP-7, MMP-8, BNP, pro-BNP and NTproANP; p<0.05. Diffuse fibrosis
was associated with GDF-15, Tenascin-C, MMP-2, MMP-3, MMP-7, BNP, proBNP and
NTproANP; p<0.05. Composite event rates (median 1446 days follow-up) did not differ
between HFpEF and HFrEF (Log-Rank p = 0.784).
Conclusions
HFpEF is a distinct pathophysiological entity compared to age- and sex-matched HFrEF
and controls. HFpEF and HFrEF are associated with similar adverse outcomes. Inflamma-
tion is common in both HF phenotypes but cardiomyocyte stretch/stress is greater in HFrEF.
Introduction
Heart failure with preserved ejection fraction (HFpEF) represents a growing yet incompletely
understood clinical entity[1]. While heart failure with reduced ejection fraction (HFrEF) has
been extensively studied, with a compelling evidence base, similar data are lacking in HFpEF
[1]. Furthermore, whether HFpEF and HFrEF are part of the same syndrome or separate enti-
ties, remains subject to debate[2]. Most epidemiological and clinical trial data on HFpEF are
based on imaging with echocardiography[3]. Cardiovascular magnetic resonance imaging
(CMR) is the recognized gold standard for the majority of imaging parameters that comprise
latest guidance on HFpEF, as well as for right ventricular (RV) assessment[1]. Furthermore,
CMR provides unique tissue characterization properties for assessment of the extra-cellular
space, namely late gadolinium enhancement imaging (LGE) for focal fibrosis[1, 4] and pre and
post-contrast T1 mapping for extracellular volume (ECV)[5] quantification, a surrogate of
interstitial fibrosis, both of which are implicated in HFpEF pathophysiology[2].
However, in-depth phenotyping of such HF groups with integrated CMR and extensive
plasma biomarker profiling has yet to be performed. In this prospective, observational study,
we compared CMR, echocardiography and circulating biomarkers between HFpEF, HFrEF
and controls with the aim of gaining pathophysiological insights into the HFpEF syndrome.
We further assessed whether clinical outcomes differed across the three groups.
Materials and methods
Study population
All subjects were recruited at a single tertiary cardiac centre as part of a prospective, observa-
tional, cohort study. The inclusion criteria for the HF groups were clinical[6] or radiographic
evidence of HF and left ventricular EF on transthoracic echocardiography (TTE) of�50% for
HFpEF or <40% for HFrEF. The exclusion criteria were: documented myocardial infarction
(MI) in the preceding 6 months, suspected or confirmed cardiomyopathy (e.g. HCM, amyloid)
or constrictive pericarditis, severe native valve disease, non-cardiovascular life expectancy <6
months, severe pulmonary disease (forced expiratory volume [FEV1]<30% predicted or
forced vital capacity [FVC] <50% predicted), estimated glomerular filtration rate (eGFR) <30
ml/min/m2 and standard contraindications to CMR[4, 7]. At the time of study conception and
conduct, owing to conjecture and lack of international consensus[2] regarding the existence of
and clear diagnostic thresholds for HFpEF, patients with with mid-range EF (HFmrEF) were
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excluded to avoid uncertainty in the characterisation of HFpEF. The presence of diastolic dys-
function was not chosen as an inclusion criterion for HFpEF diagnosis since contemporary
clinical trial data has also highlighted its presence at rest in only two thirds of HFpEF patients
[8, 9]. Furthermore, elevated natriuretic peptides were also not a requirement for HFpEF diag-
nosis in our study since normal levels of natriuretic peptides have previously been observed in
a significant proportion of such patients[8, 10].
Since the primary focus of our study was phenotyping HFpEF, we enrolled consecutively
approached patients. HFrEF and control subjects were then recruited towards the end of the
study. While it is well recognised from epidemiological data[3, 8, 11] that HFpEF patients are
older and more frequently female, age- and sex-matching was performed in the HFrEF and
control groups in order to limit the number of confounding variables.
Asymptomatic controls without known cardiac disease were recruited. Controls were
recruited through advertising and none had been referred for a clinical CMR scan. Fourteen
volunteers had also served as healthy controls in another study at our centre[12]. We did not
exclude hypertensive controls (n = 19) since hypertension is highly prevalent in the general
population without heart failure and is strongly associated with incident HFpEF[13] and we
wanted to account for this potential confounder.
All subjects underwent comprehensive clinical assessment, blood sampling, TTE and CMR,
completed the Minnesota Living with Heart Failure (MLHF) questionnaire[14] and six-minute
walk test (6MWT)[15]. At baseline, coronary artery disease (CAD) was defined as either
patient self-reporting of anginal symptoms, documented MI, coronary angiographic vessel
luminal stenosis of�70% and/or coronary revascularisation based upon patients’ medical rec-
ords. The results from the latest (last) chest radiographic reports prior to patients’ study visit
were sourced from the electronic Hospital Radiology reporting systems. The study was
approved by the United Kingdom National Research Ethics Service (reference: 12/EM/0222).
Informed consent was provided by all subjects prior to participation. The study was conducted
according to the Declaration of Helsinki and was registered with ClinicalTrials.gov
(NCT03050593).
Plasma biomarker assessment
At recruitment, blood was sampled for B-type natriuretic peptide ([BNP]—immunoassay, Sie-
mens, Erlangen, Germany), haematocrit, haemoglobin, troponin-I (normal�40 ng/L, ultra-
sensitive, sandwich chemiluminescence assay, ADVIA 2400 analyser, Siemens, Erlangen,
Germany) and renal function. Residual supernatant plasma was stored at -80˚C in cryotubes
prior to batch analysis at a later stage using a Luminex1 bead-based multiplex assay[16],
enabling high-throughput biomarker profiling as previously described[17].
The following plasma biomarkers implicated in HF and also recently evaluated using the
same assay in the TOPCAT HFpEF clinical trial[18, 19] were profiled: suppression of tumori-
gencity-2 (ST2), galectin3, growth differentiation factor-15 (GDF-15), Tenascin-C, tissue
inhibitor of metalloproteinases (TIMP-1, TIMP-4), matrix metalloproteinases (MMP-2,
MMP-3, MMP-7, MMP-8, MMP-9), pro-BNP, N-terminal pro-atrial natriuretic peptide
(NTpro-ANP), renin, myeloperoxidase, highly-sensitive C-reactive protein (hs-CRP), tumour
necrosis factor receptor-1 (TNFR-1), interleukin-6, cystatin-C and neutrophil gelatinase-asso-
ciated lipocalin (NGAL). Plasma biomarkers (total 22) were further categorized as either sur-
rogates of myocardial interstitial fibrosis, LV cardiomyocyte stress/damage, myocardial
hypertrophy, inflammation/oxidative stress, atrial wall stress/stretch or markers of renal dys-
function[20–22]. The assay ranges inclusive of upper and lower limits of quantitation, respec-
tive dilution factors and detailed analytical methods for each Luminex multiplexed plasma
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biomarker assay (Bristol Myers Squibb, Ewing Township, New Jersey, USA) are shown in S1
Table.
Transthoracic echocardiography
Echocardiography was performed by accredited sonographers in accordance with American
Society of Echocardiography guidelines using an iE33 system (Philips Medical Systems, Best,
The Netherlands)[7]. LVEF was calculated using the biplane method or estimated visually
where endocardial border definition was sub-optimal.
CMR protocol
All scans were performed on a 3-Tesla platform (Siemens Skyra, Erlangen, Germany) with an
18-channel cardiac coil, as reported previously[4, 7]. This included standard long and short-
axis cine imaging; basal, mid and apical short-axis pre- and post-contrast T1 mapping and
LGE imaging. A total of 0.15mmol/kg of contrast (Gadovist, Bayer Healthcare, Berlin, Ger-
many was administered.
CMR analysis
CVI42 software (Circle Cardiovascular Imaging, Calgary, Canada) was used for analysis, per-
formed by a single operator (PK) blinded to clinical data. Papillary muscles and trabeculations
were excluded from cavity volume when deriving ventricular volumes, EF and LV mass[4]. RV
systolic dysfunction (RVD) was defined as RVEF <47% based upon normative data from the
published literature utilizing the same technique[23] and our own healthy controls whereby
the lower limit of RVEF was also 47%. The biplane method[24, 25], excluding the appendage
and pulmonary veins was used to calculate left atrial (LA) volumes, LA ejection fraction, reser-
voir and conduit volumes. LA dilation[26] was defined as maximal LA volume indexed (LAVI-
max) >40ml/m2. Volumetric and mass data were indexed to body surface area.
LGE images were analyzed qualitatiavely for focal fibrosis, categorized as either absent or
present and further quantified accordingly[4]. The mid-ventricular T1 maps were analyzed for
ECV and iECV (ECV indexed to body surface area) as described previously[4]. Segments with
MI or artefact were excluded but regions of focal non-MI fibrosis were included in the final
ECV (and iECV) calculations. As reported previously[4], T1 mapping was not performed due
to the sequence not being available in 55 (24%) consecutive CMR scans (HFpEF n = 44,
HFrEF n = 7, controls n = 4). A further 4 patients with HFpEF had non-analyzable T1 maps.
Follow-up and endpoints. All subjects were followed up for the primary endpoint which
was the composite of all-cause mortality or hospitalization for HF (defined as a hospital admis-
sion for which HF was the primary reason and requiring either diuretic, inotropic or intrave-
nous nitrate therapy). Secondary outcomes were all-cause mortality and HF hospitalization.
Outcome data were obtained from hospital records. In patients with multiple events, the time
to first event was used as the censored outcome.
Statistical analysis
SPSS v22 was used for statistical analyses. Normality for continuous data was assessed using
the Shapiro-Wilk test, histograms and Q-Q plots. Normally distributed data are expressed as
mean ±SD. Non-parametric data are expressed as median (25–75% IQR). Categorical data are
expressed as absolute numbers or percentages. For comparison of normally distributed data
between the 3 groups, the one-way ANOVA with Bonferroni correction was used. For com-
parison of non-normally distributed data, the Kruskal-Wallis test was employed. The Chi-
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square or Mann-Whitney U tests were to compare categorical data, as appropriate. For addi-
tional between group comparisons, multiple linear regression was used to adjust for clinical
variables, where the dependent variable was the log transformed plasma biomarker of interest
and independent variables included age, gender, body mass index (BMI) and co-morbidities
[diabetes, hypertension, lung disease, atrial fibrillation (AF), chronic kidney disease (CKD),
CAD). Binary logistic regression was undertaken with the same adjustments to test for differ-
ences in the presence of elevated troponin-I levels between HF groups. Spearman’s rank corre-
lations were performed to detect any important associations with NTpro-ANP. Kaplan-Meier
analysis was undertaken to calculate event rates. The Log-Rank test was used to test differences
in survival curves. CMR assessments of intra-observer and inter-observer variability were
undertaken at least 4 weeks apart (by PK and JRA), on a subset of 10 randomly selected
patients (S1 Table).
Results
The overall study consort diagram including reasons for exclusion are detailed in Fig 1. CMR
was not performed due to the presence of pacemakers and such subjects were excluded from
the final analysis in 2 out of 51 confirmed HFrEF and 7 out of 182 confirmed HFpEF. All sub-
jects were recruited over a period of 26 months. The final participant was enrolled in April
2015. The final cohort comprised 234 subjects: HFpEF n = 140; HFrEF n = 46 and controls
n = 48. The majority of HF patients were diagnosed and participated in the study as out-
patients (HFpEF 57%; HFrEF 78%). All HF patients participating as in-patients had clinical
evidence of heart failure (albeit deemed stable) at the time of their study visit and were on or
had been receiving concomitant intravenous diuretic therapy.
Baseline clinical characteristics
The baseline data are summarized in Tables 1–3. All 3 groups were evenly matched for age
and sex distribution.
Controls. Hypertensive controls were older (75±6 vs 71±3 years, p = 0.006), had a higher
proportion of smokers, hypercholesterolaemia and exhibited lower exercise capacity (360
(325–423) vs 410 (378–456)m, p = 0.007) compared to non-hypertensive controls. The pres-
ence of hypertension correlated with the finding of focal fibrosis in controls (r = 0.328,
p = 0.023). Focal fibrosis (non-ischaemic in all cases) was observed in a small minority of
hypertensive controls (18%) and absent in non-hypertensive controls. There were no other sig-
nificant clinical, imaging or plasma biomarker differences between the control groups (also
see S3–S5 Tables).
HF versus controls. Compared to controls, HF patients had a significantly greater preva-
lence of CAD and diabetes, poorer renal function and higher LV filling pressures (i.e. higher
E/E’ and BNP). Exercise capacity was markedly worse in HF patients.
HFpEF versus HFrEF. Compared to HFrEF, patients with HFpEF had less CAD, higher
body mass index, less severe diastolic dysfunction (i.e. lower BNP and E/E’), more atrial fibril-
lation (AF) (31% versus 20%) and lower 6MWT distance (180m versus 210m; p = 0.038). The
MLHF score tended to be higher in HFpEF (p = 0.089) and NYHA class was similar between
groups. Abnormal chest X-ray findings were similarly prevalent in both HF groups (Table 2).
CMR
LV parameters. Compared to controls, LVEF was marginally lower in HFpEF, albeit pre-
served overall (p = 0.019). LV volumes were similar but HFpEF patients exhibited higher LV
mass and more concentric remodeling (higher mass/volume ratio). In comparison to HFpEF,
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patients with HFrEF had marked reductions in LVEF and substantially higher LV volumes
and mass but with a reduction in mass/volume ratio indicative of adverse eccentric remodel-
ing. Examples of typical CMR LV characteristics (plus additional imaging and plasma profiles)
of the HF groups are illustrated in Fig 2.
RV parameters. RVEF was lower in HFrEF compared to the other groups. RVD was
more prevalent in HFrEF (46%) compared to HFpEF (19%) and was also associated with
greater remodeling (increased RV end-systolic volumes) compared to HFpEF and controls.
LA parameters. Across the cohort and irrespective of cardiac rhythm, HF patients had
higher LA volumes and a greater proportion of dilated atria (p<0.0001). In sinus rhythm,
LAEF was lower in HF patients compared to controls and lowest in HFrEF (p<0.0001). LA
conduit function was depressed in HFrEF compared to HFpEF or controls.
Tissue characterization. Qualitatively, focal fibrosis was more prevalent in both HF
groups compared to controls and was commonest in HFrEF (controls 10%, HFpEF 47%,
HFrEF 89%, p<0.0001). Likewise, similar trends were observed for ischemic (0%; 16%; 57%)
and non-ischemic fibrosis (10%; 35%; 41%), p<0.0001 for both. A small subset of HF patients
exhibited both patterns of focal fibrosis: HFpEF n = 4 and HFrEF n = 5. The size of MI
expressed as a percentage of LV mass, was larger in HFrEF (9.8% vs 3%, p<0.0001) compared
to HFpEF. However, there was no significant difference in the extent of non-ischemic fibrosis
Fig 1. Study overview. Consort diagram illustrating recruitment and reasons for exclusion. CMR = cardiovascular magnetic resonance imaging; HCM = hypertrophic
cardiomyopathy; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; ILR = implantable loop recorder;
PAF = paroxysmal atrial fibrillation; TTE = transthoracic echocardiography.
https://doi.org/10.1371/journal.pone.0232280.g001
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(p = 0.179) between HF groups. Diffuse fibrosis (ECV, iECV) was also higher in both HF
groups compared to controls and greatest in HFrEF: controls (25%, 10.9±2.8), HFpEF (28%,
13.7±4.4), HFrEF (31%, 18.1±7.1); p<0.0001.
Table 1. Baseline clinical characteristics.
HFpEF n = 140 HFrEF n = 46 Controls n = 48 p value
Age (years) 73±9 72±8 73±5 0.820
Male (%) 68 (49) 23 (50) 24 (50) 0.977
Heart rate (b.p.m) 70±14 67±16 68±10 0.308
Systolic BP (mmHg) 145±25 132±24 Δ� 151±24 0.001
Diastolic BP (mmHg) 74±12Δ 71±17 Δ 79±10 0.006
Body mass index (kg/m2) 34±7Δ 28±6� 25±3 <0.0001
Sinus Rhythm (%) 97 (69)Δ 37 (80)Δ 48 (100) <0.0001
Atrial Fibrillation 43 (31)Δ 9 (20) 0 (0) <0.0001
Diabetes (%) 75 (54)Δ 18 (39)Δ 0 (0) <0.0001
Hypertension (%) 127 (91)Δ 25 (54)� 22 (46) <0.0001
Angina (%) 23 (16)Δ 11 (24)Δ 0 (0) 0.003
Known Myocardial infarction (%) 16 (11)Δ 19 (41)Δ� 0 (0) <0.0001
Coronary artery disease (%) 31 (22)Δ 23 (50)Δ� 0 (0) <0.0001
Asthma or COPD (%) 24 (17) 9 (20) 3 (6) 0.134
Smoking (%) 75 (54)Δ 28 (61)Δ 17 (35) 0.033
Hypercholesterolaemia (%) 69 (49) 21 (46) 18 (38) 0.367
Peripheral Vascular Disease (%) 3 (2) 3 (7) 0 (0) 0.120
TIA or CVA (%) 19 (14)Δ 5 (24)Δ 0 (0) 0.025
Betablocker (%) 95 (68)Δ 41 (89)Δ� 2 (4) <0.0001
ACEi or ARB (%) 120 (86)Δ 36 (78)Δ 10 (21) <0.0001
Aldosterone antagonist (%) 43 (31)Δ 19 (41)Δ 0 (0) <0.0001
Loop Diuretic (%) 113 (81)Δ 37 (80)Δ 0 (0) <0.0001
NYHA III/IV (%) 43 (31) 12 (26) NA 0.551
6 minute walk distance 180 (120–250)Δ 210 (165–290)Δ� 380 (350–440) <0.0001
MLWHF score 49 (25–65) 36 (22–59) NA 0.089
Sodium (mmol/L) 139±4 140±3 140±2 0.098
Urea (mmol/L) 9±4Δ 9 ± 4Δ 6±1 <0.0001
Creatinine (mmol/L) 89 (73–114.8)Δ 97 (77–128)Δ 71 (56.3–84.5) <0.0001
eGFR (ml/min/m2) 68 (52–83)Δ 61 (48–77) Δ 92 (74–100) <0.0001
CKD grade Δ Δ <0.0001
1 27 (19) 6 (13) 26 (54) -
2 54 (39) 17 (37) 20 (42) -
3 59 (42) 23 (50) 2 (4) -
Haemoglobin (g/L) 129±22Δ 134±24 140±15 0.003
Haematocrit (%) 38±6 40±7 41±4 0.071
BNP (ng/L) 135.6 (65.5–254.4)Δ 387 (178–634)Δ� 33 (24–44) <0.0001
Δ P<0.05 for HFpEF or HFrEF versus controls
�P<0.05 for HFpEF vs HFrEF
Values are mean ± SD or n (%) or median (interquartile range). ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BNP = B-type
natriuretic peptide; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CVA = cerebrovascular accident; eGFR = estimated glomerular
filtration rate; NA = not applicable; NYHA = NewYork Heart Association; TIA = transient ischaemic attack
https://doi.org/10.1371/journal.pone.0232280.t001
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Table 2. Imaging characteristics by heart failure classification.
HFpEF n = 140 HFrEF n = 46 Controls n = 48 p value
Prior Chest Radiography
Pulmonary oedema (%) 97 (69) 31 (67) NA 0.933
Raised CTR (%) 101 (72) 35 (76) NA 0.362
Pleural effusion (%) 49 (35) 21 (46) NA 0.138
Echo�
E/E’ 13±6Δ 15±5Δ� 9±3 <0.0001
LA
Overall including AF subjects
LAVImax (ml/m2) 43±19Δ 45±15Δ 30±7 <0.0001
LAVImin (ml/m2) 30±19Δ 33±16Δ 17±5 <0.0001
LAEF (%) 35±18Δ 28±15Δ 44±11 <0.0001
Sinus rhythm subjects only
LAVImax (ml/m2) 36±14Δ 43±14Δ� 30±7 <0.0001
LAVImin (ml/m2) 21±12 29±12Δ� 17±5 <0.0001
LAEF (%) 44±14 32±12Δ� 44±11 <0.0001
CMR
LV
LVEDVI (ml/m2) 79±18 142±44Δ� 81±14 <0.0001
LVESVI (ml/m2) 35±10 106±44Δ� 34±8 <0.0001
LVEF (%) 56±5Δ 28±9Δ� 58±5 <0.0001
LVEDMI (g/m2) 52±15Δ 64±22Δ� 46±9 <0.0001
LV mass/LV volume 0.68±0.16Δ 0.47±0.15Δ� 0.57±0.09 <0.0001
RV
RVEDVI (ml/m2) 80±19 86±27 83±15 0.212
RVESVI (ml/m2) 37±14 53±33Δ� 37±9 <0.0001
RVEF (%), median (range) 54 (27–74) 49 (20–72)Δ� 55 (47–70) <0.0001
RV Dysfunction (%) 25 (19)Δ 21 (46)Δ� 0 (0) <0.0001
LA
Overall including AF subjects
LAVImax (ml/m2) 53±25Δ 59±24Δ 35±12 <0.0001
LAVImin (ml/m2) 38±26Δ 44±24Δ 17± 8 <0.0001
LA reservoir volume indexed (ml/m2) 15±7 15±7 17±6 0.087
LA conduit volume indexed (ml/m2) 29±9 23±9Δ� 30±9 <0.0001
Dilated LA 90 (64)Δ 38 (83)Δ� 15 (31) <0.0001
Sinus rhythm subjects only
LAVImax (ml/m2) 43±17Δ 55±19Δ� 35±12 <0.0001
LAVImin (ml/m2) 26±13Δ 38±18Δ� 17±8 <0.0001
LA reservoir volume indexed (ml/m2) 17±6 17±6 17±6 0.957
LA conduit volume indexed (ml/m2) 28±8 22±9Δ� 30±9 <0.0001
LAEF (%) 41 ± 12Δ 33 ±12Δ� 51 ± 11 <0.0001
Dilated LA 48 (49)Δ 29 (78)Δ� 15 (31) <0.0001
LV Tissue characterization
ECV (%) 28±5Δ 31±8Δ� 25±3 <0.0001
iECV (ml/m2) 13.7±4.4Δ 18.1±7.1Δ� 10.9±2.8 <0.0001
LGE positive (%) 66 (47)Δ 41 (89)Δ� 5 (10) <0.0001
LGE positive–MI (%) 23 (16)Δ 26 (57)Δ� 0 (0) <0.0001
If MI, size of infarct as % of LV mass 3.0 (1.3–4.6) 9.8 (4.2–20.6)� NA <0.0001
(Continued)
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Table 2. (Continued)
HFpEF n = 140 HFrEF n = 46 Controls n = 48 p value
LGE positive–non-MI 49 (35)Δ 19 (41)Δ 5 (10) <0.0001
If non-MI, size of scar as % of LV mass 2.9 (1.4–6.5) 3.9 (2.2–7.7) 2.4 (0.6–3.6) 0.437
ΔP<0.05 HFpEF or HFrEF versus controls
�P<0.05 for HFpEF versus HFrEF
Values are mean ± SD or n (%). CTR = cardiothoracic ratio; ECV = extracellular volume; iECV = indexed ECV; LAEF = left atrial ejection fraction; LAVI = left atrial
volume indexed to body surface area (maximal/minimal); LVEDMI = left ventricular end-diastolic mass indexed to body surface area; LVEDVI = left ventricular end-
diastolic volume indexed to body surface area; MI = myocardial infarction; NA = not applicable; RVEF = right ventricular ejection fraction; RVEDVI = right ventricular
end-diastolic volume indexed to body surface area
https://doi.org/10.1371/journal.pone.0232280.t002
Table 3. Plasma biomarkers by heart failure classification.
HFpEF n = 140 HFrEF n = 46 Controls n = 48 p value
Interstitial fibrosis
ST-2 (ng/ml) 6386 (4956–8905)Δ 5117 (3912–8598) 5729 (4303–6940) 0.028
Galectin-3 (ng/ml) 7495 (5718–8998)Δ 7148 (6393–8859)Δ 5038 (4172–6104) <0.0001
GDF-15 (ng/ml) 2248 (1546–3585)Δ 2117 (1509–3596)Δ 955 (665–1300) <0.0001
Tenascin-C (ng/ml) 13.7 (10.8–17.3) Δ 13.1 (11.4–16.3) Δ 11.1 (8.9–12.9) <0.0001
TIMP-1 (ng/ml) 1009 (755–1379)Δ 1013 (754–1271)Δ 662 (578–890) <0.0001
TIMP-4 (ng/ml) 1.8 (1.4–2.4)Δ 1.7 (1.4–2.1)Δ 1.3 (1.2–1.6) <0.0001
MMP-2 (ng/ml) 72.8 (58.6–86.8)Δ 69.7 (64.4–87.7)Δ 62.7 (56.2–68.7) 0.003
MMP-3 (ng/ml) 6.8 (4.6–10.3)Δ 7.8 (5.1–10.7)Δ 5.7 (3.2–7.5) 0.017
MMP-7 (ng/ml) 0.6 (0.4–1.0)Δ 0.8 (0.5–1.2)Δ 0.3 (0.2–0.5) <0.0001
MMP-8 (ng/ml) 0.3 (0.2–0.4)Δ 0.3 (0.2–0.6)Δ 0.2 (0.1–0.3) <0.0001
MMP-9 (ng/ml) 27.8 (19.5–56.8)Δ 36.6 (22.8–60.2)Δ 24.5 (15.5–37.8) 0.042
LV Cardiomyocyte stress/damage
Elevated Troponin-I, ng/L (%) 33 (24)Δ 17 (37)Δ 0 (0) <0.0001
BNP (ng/L) 136 (66–254)Δ 387 (178–634)Δ� 33 (24–44) <0.0001
Pro-BNP (pg/ml) 1.6 (1.2–2.2)Δ 2.3 (1.6–4.3)Δ� 1.2 (1.1–1.4) <0.0001
Myocardial Hypertrophy
Renin (pg/ml) 389 (223–864)Δ 580 (259–1187)Δ 111 (61–202) <0.0001
Inflammation/oxidative stress
Myeloperoxidase (ng/ml) 212 (160–262)Δ 203 (147–283)Δ 153 (130–178) <0.0001
hs-CRP (ng/ml) 43169 (14992–78805)Δ 24604 (6246–67468)Δ 6914 (3531–17393) <0.0001
TNFR-1 (ng/ml) 5.4 (4.1–7.8)Δ 5.6 (3.9–7.8)Δ 3.2 (2.7–3.7) <0.0001
Interleukin-6 (pg/ml) 4.0 (3.3–5.1)Δ 3.7 (3.2–5.3)Δ 2.9 (2.5–3.2) <0.0001
Atrial stress/stretch
NTpro-ANP (pg/ml) 6443 (4362–8511)Δ 7814 (6226–10097)Δ� 4019 (3362–4475) <0.0001
Renal markers
Cystatin C (ng/ml) 776 (686–989)Δ 811 (676–996)Δ 586 (526–648) <0.0001
NGAL (ng/ml) 44.6 (32.9–58.5)Δ 48.6 (33.1–63.4)Δ 26.4 (21.2–34.3) <0.0001
Δ P<0.05 for HFpEF or HFrEF versus controls
�P<0.05 for HFpEF vs HFrEF
Values are median (IQR) or n (%). GDF-15 = growth differentiation factor-15; hs-CRP = highly-sensitive C-reactive protein; MMP = matrix metalloproteinases;
NGAL = neutrophil gelatinase-associated lipocalin; NTpro-ANP = N-terminal pro-atrial natriuretic peptide; ST2 = suppression of tumorigencity-2; TIMP = tissue
inhibitor of metalloproteinase; TNFR-1 = tumour necrosis factor receptor-1
https://doi.org/10.1371/journal.pone.0232280.t003
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Inter-observer and intra-observer assessments. Data quantification for all CMR parame-
ters are shown in S6 Table. All intra-observer agreements were excellent (co-eficient of varia-
tions<10%) and universally better than for inter-observer agreements. The majority of inter-
observer agreements remained excellent albeit LV end-systolic volumes, RV end-systolic vol-
umes and RV ejection fraction fared worse (but still good).
Plasma biomarkers
All plasma biomarkers tested in the panel except ST2 displayed higher levels in both HF groups
compared to controls. The majority of biomarkers were not different between HFpEF and
HFrEF. The exceptions were the natriuretic peptides (Fig 3) and Troponin-I. BNP, pro-BNP
and NTpro-ANP levels were highest in HFrEF. After adjusting for potential confounders
including age, sex, BMI, diabetes, hypertension, lung disease, AF and CKD, these differences
(or similarities) in plasma biomarkers between HFpEF and HFrEF persisted (see S2 Table)
with the exception of MMP-8. Likewise, following binary logistic regression and adjustments
for the same variables listed above, the presence of troponin-I elevation was different between
the HF groups (odds ratio 2.536; 95% CI 1.033–6.230; p = 0.042).
The presence of focal fibrosis on LGE correlated with the following plasma biomarkers of
interstitial fibrosis: galectin3, GDF-15, MMP-3, MMP-7, MMP-8 and cardiomyocyte stress/
stretch (BNP, pro-BNP, NTproANP); p<0.05 for all. ECV (diffuse fibrosis) also correlated
with plasma interstitial fibrotic markers (GDF-15, Tenascin-C, MMP-2, MMP-3, MMP-7) and
cardiomyocyte stress/stretch (BNP, proBNP, NTproANP); p<0.05 for all. The results of corre-
lations of imaging parameters reflecting fibrosis with plasma biomarkers are shown in S7 and
S8 Tables.
NTpro-ANP strongly correlated with: BNP r = 0.675; minimal LA volume indexed (LAVI-
min) r = 0.608; LAVImax r = 0.580; LAEF r = -0.506; p<0.0001 for all (S1 Fig). Troponin ele-
vations were only observed in the HF cohorts: HFpEF 24%; HFrEF 37%. Hs-CRP levels were
highest in HFpEF but not significantly different compared to HFrEF (p = 0.082).
Fig 2. Summary of directional change of CMR and plasma biomarkers profiles compared to controls. CMR images at the top of the
illustration. Panel A: mid-ventricular end-diastolic cines showing concentric remodeling in HFpEF and eccentric remodeling in HFrEF; Panel B:
Late gadolinium enhancement images showing (white arrows) small, sub-endocardial ischemic fibrosis in HFpEF and more extensive ischemic
fibrosis involving multiple segments in HFrEF; Panel C: Late gadolinium enhancement images showing (white arrows) non-ischemic fibrosis in
HFpEF and HFrEF; Panel D: Post-contrast mid-ventricular extra-cellular volume colour maps showing increased diffuse fibrosis in both HFpEF
and HFrEF.
https://doi.org/10.1371/journal.pone.0232280.g002
Fig 3. Plasma biomarkers that were different between HFpEF and HFrEF: Natriuretic peptides. BNP = B-type natriuretic peptide; Pro-BNP = pro-B-type natriuretic
peptide; NTpro-ANP = N-terminal pro-atrial natriuretic peptide; p<0.05 for all.
https://doi.org/10.1371/journal.pone.0232280.g003
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Sub-group analysis of HF patients excluding known CAD and/or MI on LGE. Follow-
ing exclusion of HF subjects with known CAD or with evidence of MI on LGE (n = 43 HFpEF,
n = 28 HFrEF), the higher prevalence of non-ischemic fibrosis in HFrEF compared to HFpEF
remained (72% vs 38%, p = 0.006). Furthermore, the trends for key imaging differences in
these sub-groups between HFrEF and HFpEF remained the same with respect to LVEF, LV
remodeling patterns, RVD, LA dysfunction and iECV. Likewise, higher levels of cardiomyo-
cyte stress/damage plasma biomarkers were again observed in HFrEF relative to HFpEF (see
S9–S11 Tables).
Endpoints. During median follow-up (overall 1446 [1243–1613]; HFpEF 1429 [1157–
1567]; HFrEF 1492 [1392–1545] days), the proportion of events were similar for HFpEF (67
composite events [48%], 45 HF hospitalizations, 22 deaths) compared to HFrEF (20 composite
events [43%], 14 HF hospitalizations, 6 deaths); p = 0.606. The event rates and time to first
events did not differ significantly between HFrEF and HFpEF for both primary (Log-Rank
p = 0.784) and secondary outcomes (all-cause mortality Log-Rank p = 0.372; HF hospitaliza-
tion Log-Rank p = 0.705). Kaplan-Meier survival curves stratified according to both HF groups
are shown in S2 Fig. There were no events in the control group.
Discussion
Our phenotyping study provides important insights into the clinical and pathophysiological
profiles of HFpEF relative to HFrEF and controls. Firstly, our study re-affirms the clinical het-
erogeniety of HFpEF and its association with adverse outcomes and exercise incapacity. Sec-
ondly, striking differences in CMR parameters, underscored by plasma biomarkers were seen
in both HF groups compared to controls. Thirdly, imaging differences of cardiac structure and
function were clearly evident between HFpEF and HFrEF at the chamber levels (LV, RV and
LA) as well as at the LV tissue level (focal and diffuse fibrosis). Finally, plasma markers of
inflammation, fibrosis, myocardial hypertrophy and renal dysfunction were consistently ele-
vated in both HF phenotypes but only markers of cardiomyocyte damage/loss were higher in
HFrEF compared to HFpEF.
Clinical phenotypes and characterization
Our HFpEF cohort was characterized by a high prevalence of both cardiovascular (hyperten-
sion, CAD, diabetes, AF) and non-cardiovascular disease (obesity, renal dysfunction, lung dis-
ease, anaemia), consistent with prevailing literature[3]. In addition, compared to HFrEF,
HFpEF patients had higher BMI, greater proportion of hypertension and AF but less CAD as
also noted previously[2, 3]. Both HF groups displayed markedly reduced exercise capacity and
quality of life, consistent with the diagnoses[27]. Unlike prior literature however[27], exercise
capacity was lower and HF symptoms tended to be higher in HFpEF compared to HFrEF in
our cohort. Possible explanations for this include the contribution of the greater co-morbidity
burden seen in HFpEF[28], as well as vascular stiffening and reduced aortic distensibilty[29],
measures not yet assessed in our cohort but which may further impact upon 6MWT distance.
Imaging and plasma biomarkers
As expected we observed changes in LV structure and function (systolic and diastolic) across
both HF cohorts compared to controls. However, the pattern of these changes was markedly
different between HFpEF and HFrEF. The lower LVEF in HFpEF (albeit preserved overall)
compared to controls has previously been observed with TTE and was thought to reflect mildly
reduced contractile function, subtle systolic abnormalities and impaired longitudinal function
[30]. In our HFpEF cohort, both CMR and plasma changes further explain the likely aetiology
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of such disturbances, with MI noted in a significant minority (16%), non-ischemic focal fibro-
sis in nearly half and an increased proportion of patients having evidence of cardiomyocte
damage/loss (raised Troponin-I). In contrast, LVEF was markedly reduced in HFrEF and was
associated with higher focal fibrotic burden (both MI and non-ischemic) and an even greater
proportion with elevated Troponin-I.
In agreement with previous reports[2, 3], we also observed different patterns of adverse
remodeling in HFpEF (concentric) and HFrEF (eccentric). Parameters previously implicated
in the pathophysiology of adverse remodeling in HF were also found to be elevated in our
study: interstitial fibrosis (CMR and plasma), inflammation, oxidative stress, myocardial hype-
trophy, RAAS activation, cardiomyocyte damage and renal dysfunction[20–22, 31]. Of these,
only markers of cardiomyocyte stretch/damage differed between HF groups.
Recently, alternative paradigms for HFpEF and HFrEF have been proposed[32], postulating
that prevalent co-morbidities in HFpEF induce a pro-inflammatory state which is the predom-
inant pathophysiological mechanism influencing LV remodeling. Systemic inflammation
induces microvascular endothelial dysfunction, which in turn limits nitric oxide bioavailablity,
decreasing protein kinase G activity, promoting both cardiomyocyte hypertrophy (concentric
remodeling) and stiffening (titin hypophosphorylation), with resultant myofibroblast-induced
interstitial fibrosis. In contrast, predominant cardiomyocyte damage/loss resulting in focal
(replacement) fibrosis is thought to be the main driver behind chamber dilation and eccentric
remodeling in HFrEF.
However, the data supporting the differential role of inflammation and cardiomyocyte
damage in HFpEF and HFrEF has been conflicting to. While some studies[22, 33] have shown
contrasting levels of inflammatory markers between HFpEF and HFrEF, others have shown
similar levels in both HF sub-types, as observed in our study[34]. We also noted a clear signal
for cardiomyocyte damage as the predominant mechanism in HFrEF with higher levels of
natriuretic peptides and with Troponin-I. Furthermore, CMR detected focal fibrosis was also
higher in HFrEF. Diffuse fibrosis is thought to represent vulnerable myocardium prior to the
transitory phase towards focal, irreversible (replacement) fibrosis development. Our finding of
more prevalent focal fibrosis in HFrEF is also a likely reflection of this phenomenon. Only one
prior CMR study[35] has compared diffuse fibrosis between HFpEF and HFrEF with similar
findings to the present study.
Diastolic dysfunction noted in HF is primarily governed by myocardial hypertrophy (and
stiffness), which in turn is regulated at the tissue level by alterations in cardiomyocytes and the
extracellular matrix[32]. Given that the degree of fibrosis, and consequent remodeling, is vastly
different between both HF groups, surrogates of diastolic dysfunction i.e. natriuretic peptides,
E/E’ and LA volumes were unsurprisingly higher in HFrEF. Furthermore, end-diastolic wall
stress in HFpEF is less pronounced[36], reducing the stimulus for natriuretic peptide secre-
tion. In addition, the greater prevalence of obesity in HFpEF may further blunt natriuretic
peptide levels[36].
Right ventricular dysfunction
A wide range of prevalence for RVD, primarily derived from TTE data has previously been
reported in HFpEF (4–44%), utilizing variable definitions of HFpEF e.g. LVEF�45% and dif-
ferent diagnostic thresholds for RVD (tricuspid annular plane systolic excursion, fractional
area change and RVEF)[37, 38]. There has also been conflicting data as to whether RVD preva-
lence differs between HFpEF and HFrEF[38]. In HFpEF, only 2 CMR studies have analyzed
RV performance and both lacked control groups. In the first study[39] (n = 142) significant
RVD was defined semi-quantitatively as the presence of least moderate RVD (prevalence
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12%). The second study[40] (n = 171) using a RVEF cut-off of<45% reported RVD prevalence
of 19%. To our knowledge, no prospective CMR studies have compared RVD in HFpEF and
HFrEF.
Our study confirms that RVD is present in a significant minority of HFpEF and is also
more prevalent in HFrEF compared to HFpEF, based upon our own internal reference con-
trols. RVD may be part of the natural aetiological profile in HFpEF whereby biventricular
remodeling often co-exists, even in early stages[41] or as a marker of prognosis[37]. The high
concurrent burden of lung disease, CAD and diastolic dysfunction have all previously been
implicated in the aetiology of RVD in HFpEF[37]. Our findings of a greater degree of RVD in
HFrEF compared to HFpEF is likely explained in part by the higher proportion of CAD
(ischaemia and MI) in our HFrEF group which is intrinsically linked to impaired RV contrac-
tility[38]. Furthermore, impaired LV contractility is also known to indirectly impair RV per-
formance[42].
LA dysfunction and remodeling
In our study, compared to controls, both HF groups displayed more adverse LA remodeling
and dysfunction, irrespective of AF. Our findings are further supported by the differential lev-
els of NTpro-ANP (a marker of atrial as well as cardiomyocyte stress/stretch) observed across
all groups and its strong correlations with LAEF and LA volumes.
Our work is additive to the growing evidence base implicating these parameters in HF[43].
Impaired LA function has also been noted in antecedent conditions of HF (e.g. diabetes,
hypertension) even in the presence of normal LA size[44]. Similar to our findings, lower LAEF
has been previously shown in HFpEF compared to hypertensive subjects with LV hypertrophy
[45]. Furthermore, a trend towards worse LAEF in HFrEF when compared to HFpEF has also
been reported using TTE[46]. In that study, analogous to structural changes in the LV, HFrEF
displayed more eccentric LA remodeling whilst HFpEF was characterized by higher LA wall
stress. In our study, worsening LA dilation was observed in HFrEF compared to HFpEF, even
in the absence of AF. Furthermore, the differing degrees of LAEF reduction and LA remodel-
ing seen in our HF groups mirrored the degree of adverse remodeling in the LV, suggesting
indirect upstream LA consequences. This hypothesis is further supported by the strong corre-
lation of NTpro-ANP, a more specific marker of LA stress/stretch than BNP.
Implications
HFpEF has been the subject of ongoing debate as to whether it truly exists or it is just a collec-
tion of co-morbidities in elderly subjects that ultimately drive symptoms and outcomes[2, 3].
Our study provides supportive evidence that HFpEF is a clinical entity distinct from controls
and HFrEF and is characterized by pathophysiological disturbances across a range of both
CMR and plasma biomarker measures, even when accounting for the influence of age, sex and
additional comorbidity.
Our group has previously shown[7] that in those with ‘suspected’ HFpEF who underwent
standard evaluation with echocardiography, utilizing CMR identifies new (27%), previously
undiagnosed clinical pathologies (e.g. HCM, constrictive pericarditis) which may alternatively
account for symptoms but also are independently predictive of prognosis. In this current
study, following exclusion of such pathologies, we were able to study a ‘purer’ cohort of
HFpEF.
The structural and functional changes observed in our HFpEF cohort may also carry prog-
nostic relevance and have ramifications for future clinical trial design and therapies. Worse
outcomes have been previously shown in the presence of adverse LV remodeling[47], focal
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fibrosis[48] and RVD[39, 40] in HFpEF. We have also shown that diffuse fibrosis (iECV and
ECV)[49] and LA dysfunction[24] are independently related to prognosis in our HFpEF
cohort. The distinct patterns of LV remodeling seen in the HF groups and the greater degree
of cardiomyocyte damage/stress seen in our HFrEF cohort also provide potential insights into
the failure of traditional HFrEF vasodilator therapies when tested in HFpEF clinical trials. The
slope of the end-systolic pressure-volume relationship (or end-systolic LV elastance), a mea-
sure of contractility is influenced by chamber size. In HFpEF, elastance is increased and
heightens sensitivity to volume changes resulting in substantial vasodilator-induced blood
pressure (BP) reductions. In HFrEF however, elastance is diminished and similar therapy
improves stroke volume without such BP drops[50]. Finally, CMR potentially enables HFpEF
to be further sub-categorised into clinical phenotypes e.g. ischemic versus non-ischemic and
pathophysiological sub-types enabling more targeted therapies as recently proposed[2]. Inte-
grating plasma markers not only provides supportive measures for CMR derangements, but
could also serve as potential biomarkers to assess treatment response[31]. LA dysfunction is a
potential treatment target in HFpEF[51] and the use of CMR-derived LAEF and NT-proANP
may serve as useful outcome measures in this setting. Furthermore, the association of plasma
biomarkers of interstitial fibrosis and cardiomyocyte stress/damage with LGE and ECV in our
study may be of potential benefit where fibrosis is the focus of treatment strategies in HFpEF
[52]. Our study adds to the growing data for the associations of plasma biomarkers with CMR
measures of fibrosis. MMP-2, galectin-3[53] and BNP[54] have previously been show to corre-
late with ECV in HFpEF. In severe aortic stenosis patients[55], phenotypically similar to
HFpEF, both ECV and LGE have also been shown to correlate with NTpro-BNP. Even in sub-
jects free of cardiovascular disease, NTpro-BNP also correlated with ECV in the MESA study
[56].
Strengths and limitations
We tested an extensive array of biomarkers reflecting individual domains which provides a
more unbiased approach to discriminating key pathophysiological differences between our
cohorts. Furthermore, such changes in biomarker profiles corroborate the CMR findings.
While imaging parameters have been used to characterise HFpEF previously, these have largely
been from echocardiographic data. Prior CMR studies in this setting have not only been sparse
but largely confined to assessment of individual characteristics such as the LV, RV or diffuse
fibrosis and lacking controls or HFrEF groups for comparison. Our study is the first to under-
take a comprehensive and combined assessment of all of the above parameters as well as quan-
tifying focal fibrosis, using a novel metric of diffuse fibrosis (iECV) and undertaking RV and
LA volumetric and EF measurements across all 3 groups.
This is a single centre, observational study with possible selection bias. Therefore, the results
should be confirmed in additional populations. We do not have additional information
regarding the duration of HF. A small proportion of subjects did not undergo CMR due to the
presence of pacemakers. At the time of study conduct, our centre was not implanting CMR
conditional devices. We recognize that the unequal group sizes and higher number of patients
in the HFpEF group are potentially confounding. However, we minimized the effects of age
and sex by matching for these variables between the groups. Furthermore, we accounted for
additional comorbidities in our statistical analysis. We deliberately chose a higher HFpEF sam-
ple size in our study since HFpEF is widely recognized to be a more heterogenous entity rela-
tive to HFrEF[1]. We did not account for additional co-morbidities such as prior
chemotherapy/radiotherapy or other systemic conditions which may have influenced plasma
biomarker levels as well as imaging markers of fibrosis.
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Coronary angiography was only performed if clinically indicated. Furthermore, the HFrEF
group had a higher proportion who underwent coronary angiography (24/46) compared to
HFpEF (27/140). Therefore, we cannot exclude a higher prevalence of undiagnosed CAD in
the HFpEF group which may account for some differences in plasma biomarker levels between
the groups. Prior literature has consistently revealed a higher comorbidity burden in HFpEF
compared to HFrEF[8, 11]. Indeed, obesity and hypertension were more prevalent in our
HFpEF group compared to HFrEF. However, whilst the proportion of additional comorbidi-
ties such as diabetes and AF were also greater in HFpEF compared to HFrEF, this did not
reach statistical significance, likely a reflection of our sample size. The lack of differences in
prevalent lung disease and CKD between our HF groups however is most likely a consequence
of our inclusion criteria and some selection bias. We excluded patients with severe lung disease
which may alternatively explain HF symptoms. Furthermore, severe renal dysfunction (i.e.
eGFR<30) was a contraindication for CMR evaluation with contrast administration. While
the higher BMI levels in our HFpEF cohort compared to HFrEF are consistent with prior
observations[8, 11, 57], the mean BMI [28] in our HFrEF group relative to healthy controls
was also elevated. However, BMI tends to lessen with advancing and indeed more severe
HFrEF. Our HFrEF cohort comprised relatively stable, ambulant patients who probably had
less severe HF as reflected by only a small minority exhibiting NYHA class III/IV (26%). The
mean BMI and proportion of NYHA III/IV seen in our HFrEF group was also similar to that
observed in recent large, contemporary randomised control clinical trials of HFrEF (PARA-
DIGM-HF[58], DAPA-HF[59]). Furthermore, our controls were relatively lean with only a
handful being obese (8%) likely exaggerating the differences relative to HFrEF. As the HFrEF
cohort were age and sex-matched to the HFpEF population and were not consecutively
enrolled, they may not be representative of the general population with HFrEF, albeit similar
in demographics to recent large phase III clinical HFrEF trials as reported above[58, 59].
We measured Troponin-I with a validated assay routinely used by our institution at the
time of our study. We do recognise however that this assay has been superceded by more
highly sensitive measures of troponin-I with lower limits of detection and which have shown
increased troponin-I levels above the 99th percentile upper reference limit in the majority of
HF patients[60–62]. Utilising these newer assays may have enabled better troponin-I charac-
terisation and profiling between our groups. In our study, ST2 levels were higher in HFpEF
compared to HFrEF but not of statistical significance. In contrast, prior HF studies[63–66]
have demonstrated higher ST2 levels in HFrEF compared to HFpEF, each using similar assay
methodologies (ELISA) but different to our technique of ST2 quantification. This discrepancy
likely represents the possible effects of unequal sample sizes of the groups in our cohort, assay
technique and the heterogeneous nature of HFpEF itself, albeit our HFpEF sample size is the
largest to date and the technique used to measure ST2 levels has also been studied in additional
HFpEF populations[18, 19].
Study participation as in- or out-patients with differing fluid status, or recruitment of in-
patient HF patients who were receiving or had been on preceding intravenous diuretic thera-
pies may alternatively have contributed to differing plasma biomarker levels. Patient enrol-
ment into our study had already been completed by the time of publication of the latest ESC
diagnostic HF guidelines in 2016[1]. Unlike latest ESC guidance[1] however, our inclusion cri-
teria did not require the presence of diastolic dysfunction for HFpEF diagnosis nor elevated
natriuretic peptide levels. However, diastolic dysfunction is often absent at rest in approxi-
mately a third of such patients[9]. All patients with a diagnosis of HFpEF in our cohort had a
history of (or at the time of their study visit) signs and symptoms of HF as per ESC diagnostic
guidelines. In addition, at screening, a diagnostic label of HFpEF was already made by a con-
sultant Cardiologist either at a prior outpatient clinic visit or following a prior hospitalization
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episode. Only a very small minority of HFpEF patients in our cohort (12%) did not have ele-
vated BNP levels as per ESC guidelines (�35 pg/ml). However, natriuretic peptide levels well
below ESC diagnostic thresholds have previously been observed in a significant minority
(18%) of invasively proven HFpEF[10], albeit we recognize left and right heart catheterization
data is lacking in our study. In our sub-group of patients with non-elevated BNP defined as
HFpEF, a high proportion of obesity (BMI�30 kg/m2 in 81%) was observed which may addi-
tionally account for the supressed BNP levels[67]. Furthermore, our data clearly provides com-
pelling evidence (additional natriuretic peptides) that our HFpEF cohort truly had HF and the
high event rates are similar to that of previous outcome studies in HFpEF and indeed our
HFrEF cohort. Our control group also included hypertensive subjects and was therefore not
totally free of cardiovascular disease but the rationale for including such controls was to better
understand the mechanisms leading to HFpEF. If anything, this is likely to have potentially
underestimated the differences between HFpEF (and HFrEF) and control groups.
Conclusions
Compared to HFpEF, HFrEF has worse LV, LA and RV contractile function and more preva-
lent fibrosis (focal and diffuse). Both HFpEF and HFrEF are associated with similar adverse
outcomes. While inflammation is common in both HF phenotypes, cardiomyocyte stretch/
stress is greater in HFrEF suggesting that HFpEF is a distinct clinical entity.
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